Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
11/2005
11/23/2005EP1598349A1 Novel 2-pyridinecarboxamide derivatives
11/23/2005EP1598346A1 Process for producing acid adduct salt of polyacidic base compound
11/23/2005EP1598345A1 Benzopyran compounds, process for preparing the same and their use
11/23/2005EP1598340A1 1-(4-piperidinyl)-1,3-dihydro-2h-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
11/23/2005EP1598339A1 1-(4-amino-cyclohexyl)-1,3-dihydro-2h-benzimidazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
11/23/2005EP1598338A1 1-(4-piperidinyl)-1,3-dihydro-2h-indole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
11/23/2005EP1598072A1 Medical drug containing fine particle of noble metal
11/23/2005EP1598071A1 Superoxide anion decomposing agent
11/23/2005EP1598063A1 Synergic compositions comprising vitamins, minerals and trace elements to stimulate removal of intracellular lipids
11/23/2005EP1598054A2 Method of suppressing appetite
11/23/2005EP1597276A1 Therapeutic molecules
11/23/2005EP1597259A1 Nitrogen-substituted hexahydropyrazino 1,2-a]pyrimidine-4,7-dione derivatives, method for the production and use thereof as medicaments
11/23/2005EP1597247A1 Substituted 3-(benzoylureido)-thiophene derivatives, method for the production and use thereof
11/23/2005EP1597245A1 Benzothiazepine and benzothiepine derivatives
11/23/2005EP1597228A2 Substituted n-arylheterocycles, method for production and use thereof as medicaments
11/23/2005EP1597223A2 Hydroxyl compounds and compositions for cholesterol management and related uses
11/23/2005EP1596850A1 Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function
11/23/2005EP1463721B1 Compounds for imaging alzheimer's disease
11/23/2005EP1377550B9 Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors
11/23/2005EP1320372B1 Use of sulfatides for treating diabetes
11/23/2005EP1280777B1 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
11/23/2005EP1258249B1 Oral preparations for diabetes
11/23/2005EP1250124B1 Slimming cosmetic composition comprising as active agent a plant extract containing a plant natriuretic peptide (pnp)
11/23/2005EP1200831B1 Modulating binding site on potassium channels used for screening
11/23/2005EP1163528B1 Prediction of diabetes impaired wound healing
11/23/2005EP1137401B1 Administration of neurotrophic agents to the central nervous system
11/23/2005EP1037624B1 Use of conjugated linoleic acid for treating type ii diabetes
11/23/2005EP0958357B1 Novel method for testing the differentiation status in pancreatic cells of a mammal
11/23/2005EP0925293B1 Method of producing an extruded nutritional supplement product
11/23/2005CN1701068A Novel compounds and their use
11/23/2005CN1699410A Apolipoprotein A-1 agonists and their use to treat dyslipidemic disorders
11/23/2005CN1699383A Novel aryl fructose-1,6-bisphosphatase inhibitors
11/23/2005CN1699346A Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
11/23/2005CN1698601A Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use
11/23/2005CN1228335C Crystal choline ascorbate
11/23/2005CN1228325C Biguanide derivatives
11/22/2005US6967245 Ucp5
11/22/2005US6967218 Pravastatin pharmaceutical formulations and methods of their use
11/22/2005US6967216 Neuropeptide Y receptor modulators; treating eating disorders
11/22/2005US6967210 Multiple sclerosis, brain disorders, analgesics
11/22/2005US6967204 Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors
11/22/2005US6967201 Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
11/22/2005US6967199 Substituted diamine derivatives useful as motilin antagonists
11/22/2005US6967193 phosphonate group-containing purine derivatives; for preventing type II diabetes
11/22/2005US6967100 Propagating islet of langerhans cells; obtain cells, culture in presence of bone morphogenic protein or modulator, monitor proliferation of cells
11/22/2005US6967097 Nucleotide sequences coding enzymatic polypeptide for use in the treatment of viral diseases
11/22/2005US6967094 Peptide for use in treatment of cancer, parkinson's and metabolic disorders
11/22/2005US6967089 Delivery system for porcine somatotropin
11/22/2005US6967023 solidifying agent consists of a long chain fatty alcohol having at least 15 carbon atoms in its backbone and a fatty acid having at least 18 carbons in its backbone; carrier is semi-solid at rest and liquefies upon application of shear forces
11/22/2005US6967019 Production of pancreatic islet cells and delivery of insulin
11/22/2005CA2153348C Enteral diet and method for providing nutrition to a diabetic
11/17/2005WO2005108400A1 Pyridoquinazoline derivatives having heterobicyclic substituents
11/17/2005WO2005108399A1 Imidazopyridine compound
11/17/2005WO2005108370A1 Benzene compounds
11/17/2005WO2005107783A1 Food containing extract from bark of pine
11/17/2005WO2005107778A1 Body fat reducing preparation
11/17/2005WO2005107759A1 Bh4-responsive hyperphenylalaninemia remedies
11/17/2005WO2005107746A1 Pharmaceutical composition for prevention or treatment of lipid metabolism disorder
11/17/2005WO2005107737A1 Antifatigue composition
11/17/2005WO2005107734A1 Alcohol metabolism accelerating composition, and food or drink containing the composition
11/17/2005WO2005107498A1 Food containing polyphenol
11/17/2005US20050257278 Transgenic non-human animals expressing a truncated activin type II receptor
11/17/2005US20050256336 Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine
11/17/2005US20050256333 4-(3-(2,6-Dimethoxybenzyloxy)phenyl)-4-oxobutyric acid or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis
11/17/2005US20050256326 Process for decreasing environmental pollutants in an oil or a fat, a volatile environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
11/17/2005US20050256317 Reacting a 5-thio-D-aldohexopyranose derivative with a hydroxyaromatic compound in the presence of a phosphine and an azo reagent; Mitsunobu reaction conditions; useful as an sodium-dependent glucose transporter (SGLT2) inhibitor; beta-selective glycosylation
11/17/2005US20050256316 Preparation of phosphatase inhibitors
11/17/2005US20050256315 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
11/17/2005US20050256302 Novel peptides having camp producing activity
11/17/2005US20050256198 2-[(4-{3-[benzyl(hexyl)amino]-3-oxopropyl}phenoxy)methyl]benzoic acid;peroxisome proliferator-activated receptors alfa agonist; antidiabetic, hypotensive agent; obesity, elevated VLDL (Very Low Density Lipoproteins) and reduced HDL (High Density Lipoprotein) concentrations
11/17/2005US20050256178 Novel nutraceutical compositions comprising boitin
11/17/2005US20050256172 1-(3-Pyridyl-2-(N-(2-(3,4-dichlorophenyl)ethyl-N-propylamino)ethanol and a dihydrobromide salt; ligands of sigma receptors; sterol Delta 7,8-isomerase inhibitors; anticholesterol agents; antilipemic agents; hypercholesterolemia and hyperlipemia; side effect reduction due to more targeted action
11/17/2005US20050256167 Preparation and use of imidazole derivatives for treatment of obesity
11/17/2005US20050256166 Nitrogen-containing compounds
11/17/2005US20050256160 Beta-alanine derivatives and the use thereof
11/17/2005US20050256142 New purine derivatives
11/17/2005US20050256140 Condensed pyridines and pyrimidines with tie2 (tek) activity
11/17/2005US20050256134 Use of creatine analogues and creatine kinase modulators for the prevention and treatment of glucose metabolic disorders
11/17/2005US20050256119 selective serotonine (5-HT) reuptake inhibitor activity in combination with additional alpha 2-adrenocptor antagonist activity; To treat anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders including anorexia nervosa and bulimia without being sedative
11/17/2005US20050256117 Ophthalmic compositions for treating ocular hypertension
11/17/2005US20050256108 avoid the adverse side effects associated with non-selective receptor interactions; 1-(4-Fluorobenzyl)-2-(4-methoxybenzyl)-8-methyl-1,2,8-triaza-spiro[4.5]decan-3-one; 1-oxa-4,9-diaza-spiro[5.5]undecan-3-one compounds as monoamine receptor modulators; schizophrenia, psychosis, migraine, hypertension
11/17/2005US20050256079 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
11/17/2005US20050256053 Combined use of a GLP-1 compound and another drug for treating dyslipidemia
11/17/2005US20050256051 Nuclear receptor-mediated introduction of a PNA into cell nuclei
11/17/2005US20050256033 Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
11/17/2005US20050256031 Composition for relieving discomfort
11/17/2005US20050255576 PGDS inhibitor; antiallergies, sleep control, antiobesity and brain wound healing; Crystals of a complex of human origin hematopoietic prostaglandin D synthase, glutathione and a substrate analog or an inhibitor
11/17/2005US20050255549 IRAK-4: compositions and methods of use
11/17/2005US20050255156 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
11/17/2005US20050255126 biologically pure strain of Aureobasidium pullulans isolated from a food source; culturing in a medium containing saccharides as a carbon source; has resistance to the antibiotic cycloheximide
11/17/2005US20050255113 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
11/17/2005US20050255111 Use of an inhibitor or antagonist against tissue factor
11/17/2005DE10392697T5 Herstellung und Standardisierung von immunmodulierenden Peptid-verknüpften Glucanen mit nachweisbarer oraler Resorbierbarkeit aus Coriolus Versicolor Preparation and standardization of immunomodulating peptide-linked glucans with detectable oral absorbability from Coriolus Versicolor
11/17/2005CA2566433A1 Therapeutic agent for bh4-responsive hyperphenylalaninemia
11/17/2005CA2566398A1 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
11/17/2005CA2566184A1 Imidazopyridine compound
11/17/2005CA2566083A1 Antifatigue composition
11/17/2005CA2565878A1 Pharmaceutical composition for prevention or treatment of lipid metabolism disorder
11/17/2005CA2565630A1 Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
11/17/2005CA2565250A1 Cysteamines for treating complications of hypercholesterolemia and diabetes
1 ... 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 ... 1298